PULMONX CORPORATION Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
PULMONX CORPORATION (LUNG) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 128.40 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-03-10
- PULMONX CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- PULMONX CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 0.00 shares.
- PULMONX CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- PULMONX CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-03-31 was 128.40K shares, a 79.88% decline year-over-year.
- PULMONX CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 128.40K shares, a 86.17% decline from fiscal 2024.
- PULMONX CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 928.13K shares, a 11.10% increase from fiscal 2023.
- PULMONX CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 835.40K shares, a 9.07% increase from fiscal 2022.
- PULMONX CORPORATION share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 765.90K shares, a 81.84% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | 0.00 shares derived: sum of 2 quarters · filed 2026-03-10 | 0.00 shares derived: sum of 3 quarters · filed 2026-03-10 | 128.40K shares 10-K · filed 2026-03-10 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | 0.00 shares derived: sum of 2 quarters · filed 2025-11-12 | 128.40K shares 10-Q · filed 2025-11-12 | 161.40K shares derived: sum of 4 quarters · filed 2026-03-10 |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-01 | 128.40K shares 10-Q · filed 2025-08-01 | 161.40K shares derived: sum of 3 quarters · filed 2026-03-10 | 161.40K shares derived: sum of 4 quarters · filed 2026-03-10 |
| 2025-03-31 | 128.40K shares 10-Q · filed 2025-05-02 | 161.40K shares derived: sum of 2 quarters · filed 2026-03-10 | 161.40K shares derived: sum of 3 quarters · filed 2026-03-10 | 418.50K shares derived: sum of 4 quarters · filed 2026-03-10 |
| 2024-12-31 | 33.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | 33.00K shares derived: sum of 2 quarters · filed 2026-03-10 | 290.11K shares derived: sum of 3 quarters · filed 2026-03-10 | 928.13K shares 10-K · filed 2026-03-10 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-01 | 257.11K shares derived: sum of 2 quarters · filed 2024-11-01 | 895.13K shares 10-Q · filed 2024-11-01 | 895.13K shares derived: sum of 4 quarters · filed 2025-02-25 |
| 2024-06-30 | 257.11K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | 895.13K shares 10-Q · filed 2024-08-02 | 895.13K shares derived: sum of 3 quarters · filed 2025-02-25 | 895.13K shares derived: sum of 4 quarters · filed 2025-02-25 |
| 2024-03-31 | 638.02K shares 10-Q · filed 2024-05-03 | 638.02K shares derived: sum of 2 quarters · filed 2025-02-25 | 638.02K shares derived: sum of 3 quarters · filed 2025-02-25 | 638.02K shares derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | 0.00 shares derived: sum of 2 quarters · filed 2025-02-25 | 0.00 shares derived: sum of 3 quarters · filed 2025-02-25 | 835.40K shares 10-K · filed 2025-02-25 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | 0.00 shares derived: sum of 2 quarters · filed 2023-11-03 | 835.40K shares 10-Q · filed 2023-11-03 | 916.10K shares derived: sum of 4 quarters · filed 2024-02-27 |
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | 835.40K shares 10-Q · filed 2023-08-04 | 916.10K shares derived: sum of 3 quarters · filed 2024-02-27 | 946.10K shares derived: sum of 4 quarters · filed 2024-02-27 |
| 2023-03-31 | 835.40K shares 10-Q · filed 2023-05-08 | 916.10K shares derived: sum of 2 quarters · filed 2024-02-27 | 946.10K shares derived: sum of 3 quarters · filed 2024-02-27 | 946.10K shares derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-12-31 | 80.70K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | 110.70K shares derived: sum of 2 quarters · filed 2024-02-27 | 110.70K shares derived: sum of 3 quarters · filed 2024-02-27 | 765.90K shares 10-K · filed 2024-02-27 |
| 2022-09-30 | 30.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 30.00K shares derived: sum of 2 quarters · filed 2022-11-08 | 685.20K shares 10-Q · filed 2022-11-08 | 685.20K shares derived: sum of 4 quarters · filed 2023-03-01 |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | 655.20K shares 10-Q · filed 2022-08-08 | 655.20K shares derived: sum of 3 quarters · filed 2023-03-01 | 655.20K shares derived: sum of 4 quarters · filed 2023-03-01 |
| 2022-03-31 | 655.20K shares 10-Q · filed 2022-05-09 | 655.20K shares derived: sum of 2 quarters · filed 2023-03-01 | 655.20K shares derived: sum of 3 quarters · filed 2023-03-01 | 1.07M shares derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | 0.00 shares derived: sum of 2 quarters · filed 2023-03-01 | 412.60K shares derived: sum of 3 quarters · filed 2023-03-01 | 421.20K shares 10-K · filed 2023-03-01 |
| 2021-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | 412.60K shares derived: sum of 2 quarters · filed 2021-11-09 | 421.20K shares 10-Q · filed 2021-11-09 | 471.00K shares derived: sum of 4 quarters · filed 2022-03-01 |
| 2021-06-30 | 412.60K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | 421.20K shares 10-Q · filed 2021-08-10 | 471.00K shares derived: sum of 3 quarters · filed 2022-03-01 | |
| 2021-03-31 | 8.60K shares 10-Q · filed 2021-05-12 | 58.40K shares derived: sum of 2 quarters · filed 2022-03-01 | ||
| 2020-12-31 | 49.80K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | 1.47M shares 10-K · filed 2022-03-01 | ||
| 2020-09-30 | 1.42M shares 10-Q · filed 2020-11-13 | |||
| 2019-12-31 | 1.08M shares 10-K · filed 2021-03-15 | |||
| 2018-12-31 | 255.90K shares 10-K · filed 2021-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SkinHealth Systems Inc. (SKIN) | United States | $0.086B | -3.17 |
| LENSAR, Inc. (LNSR) | United States | $0.087B | 2.02 |
| RenovoRx, Inc. (RNXT) | United States | $0.076B | -3.62 |
| Microbot Medical Inc. (MBOT) | $0.089B | -7.97 | |
| FRACTYL HEALTH, INC. (GUTS) | United States | $0.075B | -1.18 |
| CVRx, Inc. (CVRX) | United States | $0.067B | -2.62 |
| DarioHealth Corp. (DRIO) | $0.066B | -1.39 | |
| TELA Bio, Inc. (TELA) | United States | $0.057B | -0.82 |
| Xtant Medical Holdings, Inc. (XTNT) | United States | $0.053B | |
| Spectral AI, Inc. (MDAI) | United States | $0.052B |